menopausal. Menopausal and other perimenopausal disorders
Conditions
Interventions
Intervention 1: Control group: no intervention will take on them and do not take piascledine. Intervention 2: Case group (number1): will take one piascledine 300 mg pill daily, during three months.
p
Treatment - Drugs
Case group (number2): will take two piascledine 300 mg pill daily, during three months. piascledine should be used with food and a glass of water.
Control group: no intervention will take on them and do not take piascledine.
Case group (number1): will take one piascledine 300 mg pill daily, during three months.
piascledine should be used with food and a glass of water.
Sponsors
Jahrom University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria: menopausal women that have not menstural cycle among last one year; having hotflashes according to kuperman index; do not take another treatment such as hormone replacement, food supplements and plantal drugs. Exclusion criteria: nonmenopausal women; do not have hotflashing according to kuperman index; taking hormone replacement therapy; women can not continue using drug beacuse of gastrointestinal complication or other things.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hotflashes. Timepoint: Before intervention and in first, second and third month after intervention. Method of measurement: Scoring is from 0 to 3 according to: not at all (0), a little (1), quite a bit (2), Extremely (3). then the hotflashes score will multiply to 4.;Paraesthesia. Timepoint: Before intervention and in first, second and third month after intervention. Method of measurement: Scoring is from 0 to 3 according to: not at all (0), a little (1), quite a bit (2), Extremely (3). then the paraesthesia score will multiply to 2.;Iinsomnia. Timepoint: Before intervention and in first, second and third month after intervention. Method of measurement: Scoring is from 0 to 3 according to: not at all (0), a little (1), quite a bit (2), Extremely (3). then the insomnia score will multiply to 2.;Nervousness. Timepoint: Before intervention and in first, second and third month after intervention. Method of measurement: Scoring is from 0 to 3 according to: not at all (0), a little (1), quite a bit (2), Extremely (3). then the nervousness score will multiply to 2.;Melancholia. Timepoint: Before intervention and in first, second and third month after intervention. Method of measurement: Scoring is from 0 to 3 according to: not at all (0), a little (1), quite a bit (2), Extremely (3). then the melancholia score will multiply to 1.;Vertigo. Timepoint: Before intervention and in first, second and third month after intervention. Method of measurement: Scoring is from 0 to 3 according to: not at all (0), a little (1), quite a bit (2), Extremely (3). then the vertigo score will multiply to 1.;Weakness. Timepoint: Before intervention and in first, second and third month after intervention. Method of measurement: Scoring is from 0 to 3 according to: not at all (0), a little (1), quite a bit (2), Extremely (3). then the weakness score will multiply to 1.;Arthralgia or myalgia. Timepoint: Before intervention and in first, second and third month after intervention. Method of m | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDoctor Athar Rasekh Jahromi
Jahrom University of Medical Sciences
Outcome results
None listed